Robert Mutter, SABCS 2022: Proton therapy and its potential benefits in the treatment of breast cancer

Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]

Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]

The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]